Research Analysts Set Expectations for SABS Q2 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Stock analysts at Brookline Capital Markets issued their Q2 2026 earnings per share estimates for SAB Biotherapeutics in a note issued to investors on Friday, May 15th. Brookline Capital Markets analyst K. Raja expects that the company will earn ($0.25) per share for the quarter. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($1.22) per share.

Other analysts have also issued research reports about the company. HC Wainwright upped their target price on SAB Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Chardan Capital upped their target price on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Rodman & Renshaw reissued a “buy” rating and issued a $13.00 target price on shares of SAB Biotherapeutics in a report on Monday, May 11th. Zacks Research raised SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Finally, Wall Street Zen lowered SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

SAB Biotherapeutics Stock Down 3.8%

SAB Biotherapeutics stock opened at $3.56 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. The firm has a market capitalization of $181.39 million, a price-to-earnings ratio of -1.69 and a beta of 0.55. SAB Biotherapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $6.60. The stock’s fifty day moving average is $3.85 and its two-hundred day moving average is $3.83.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.15).

Institutional Trading of SAB Biotherapeutics

Large investors have recently made changes to their positions in the stock. PNC Financial Services Group Inc. acquired a new stake in shares of SAB Biotherapeutics during the first quarter valued at $29,000. ADAR1 Capital Management LLC acquired a new stake in shares of SAB Biotherapeutics during the third quarter valued at $30,000. Dimensional Fund Advisors LP acquired a new stake in shares of SAB Biotherapeutics during the third quarter valued at $32,000. State of Wyoming acquired a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at $34,000. Finally, Virtu Financial LLC acquired a new stake in shares of SAB Biotherapeutics during the third quarter valued at $40,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.